Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(146 produtos)
- Bcr-Abl(102 produtos)
- EGFR(572 produtos)
- FAK(72 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(245 produtos)
- PDGFR(126 produtos)
- RAAS(87 produtos)
- Src(79 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(268 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1431 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Lidocaine Hydrochloride hydrate
CAS:<p>Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.</p>Fórmula:C14H22N2O·HCl·H2OPureza:99.95%Cor e Forma:SolidPeso molecular:288.82Albendazole
CAS:<p>Albendazole (SKF-62979) is used as a drug indicated for the treatment of a variety of worm infestations.</p>Fórmula:C12H15N3O2SPureza:98.21% - 98.76%Cor e Forma:Colorless Crystals SolidPeso molecular:265.33Barecetamab
CAS:<p>Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity.</p>Pureza:97.1% (SDS-PAGE); 96.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:LiquidGancotamab
CAS:<p>Gancotamab (MM-302) is a polyethylene glycolated liposome targeting HER2 with antitumor activity for the study of advanced HER2-positive breast cancer.</p>Pureza:96.7% (SDS-PAGE); 98.4% (SEC-HPLC) - 96.7% (SDS-PAGE); 98.4% (SEC-HPLC)Cor e Forma:LiquidN-(3-Aminopropyl)cyclohexylamine
CAS:<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Fórmula:C9H20N2Pureza:98.05% - 98.82%Cor e Forma:Pale Yellow Clear LiquidPeso molecular:156.2685Chloropyramine hydrochloride
CAS:<p>Chloropyramine hydrochloride (Alergosan) is a histamine receptor H1 antagonist.</p>Fórmula:C16H20ClN3·HClPureza:99.45% - 99.8%Cor e Forma:SolidPeso molecular:326.26Trapidil
CAS:<p>Trapidil (Avantrin) is a coronary vasodilator agent.</p>Fórmula:C10H15N5Pureza:99.42%Cor e Forma:SolidPeso molecular:205.26LC-MB12
CAS:<p>LC-MB12 is a PROTAC FGFR2 compound that degrades FGFR2 and can be used to study gastric cancer.</p>Fórmula:C43H44Cl2N10O8Pureza:99.16%Cor e Forma:SolidPeso molecular:899.78Ibuprofen
CAS:<p>Ibuprofen, an NSAID, reduces pain, inflammation, and fever by limiting prostaglandin production.</p>Fórmula:C13H18O2Pureza:99.7% - 99.81%Cor e Forma:Colorless Solid CrystallinePeso molecular:206.28ALK-IN-26
CAS:<p>ALK-IN-26 is an ALK inhibitor with potential anticancer activity.ALK-IN-26 shows antiproliferative activity against glioblastoma.</p>Fórmula:C24H23NO3SPureza:99.91%Cor e Forma:SoildPeso molecular:405.51PTC299
CAS:<p>PTC299 ((4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate) is an orally active inhibitor of VEGFA mRNA</p>Fórmula:C25H20Cl2N2O3Pureza:99.72%Cor e Forma:SolidPeso molecular:467.34Olaratumab
CAS:<p>Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be</p>Pureza:SDS-PAGE:95% SEC-HPLC:98.70%Cor e Forma:LiquidPeso molecular:147.12 kDaJI6
CAS:<p>JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor.</p>Fórmula:C19H17N3O4SPureza:98.51%Cor e Forma:SoildPeso molecular:383.42HyT36
CAS:<p>HyT36: hydrophobic tag that destabilizes fusion proteins & Her3 pseudokinase; treats cells with acute erht.</p>Fórmula:C25H44ClNO3Pureza:99.86%Cor e Forma:SolidPeso molecular:442.07Icrucumab
CAS:<p>Icrucumab, a humanized antibody, inhibits VEGFR-1 and shows antitumor effects, tested in metastatic colon cancer.</p>Pureza:> 95%Cor e Forma:LiquidPeso molecular:150 kDaMRX-2843
CAS:MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively).Fórmula:C29H40N6OPureza:98.59% - 99.63%Cor e Forma:SolidPeso molecular:488.67Thiabendazole
CAS:<p>Thiabendazole (2-(4-Thiazolyl)benzimidazole) is a benzimidazole derivative with anthelminthic property.</p>Fórmula:C10H7N3SPureza:99.14%Cor e Forma:Light Yellow PowderPeso molecular:201.25Gefitinib
CAS:<p>Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations.</p>Fórmula:C22H24ClFN4O3Pureza:99.92% - >99.99%Cor e Forma:Light-Yellow Crystalline PowderPeso molecular:446.9Ascrinvacumab
CAS:<p>Ascrinvacumab (PF-03446962): humanized IgG2 anti-ALK-1 antibody, Kd 7 nM, inhibits TGF-β, for HCC research.</p>Pureza:SDS-PAGE:95% SEC-HPLC:98.18%Cor e Forma:LiquidPeso molecular:150 kDaOltipraz
CAS:<p>Oltipraz (RP 35972) is a synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties.</p>Fórmula:C8H6N2S3Pureza:98.79% - 99.77%Cor e Forma:SolidPeso molecular:226.34Trastuzumab deruxtecan
CAS:<p>Trastuzumab deruxtecan (T-DXd) is an ADC with anticancer and antitumour activity that has been shown to improve gastric cancer.</p>Pureza:95% - SEC-HPLC:98.49%Cor e Forma:LiquidPeso molecular:145 kDa (average)Hexylresorcinol
CAS:<p>Hexylresorcinol (4-Hexylresorcinol) is a substituted dihydroxybenzene used topically as an antiseptic for the treatment of minor skin infections.</p>Fórmula:C12H18O2Pureza:99.26% - 99.51%Cor e Forma:Solid Solid Particulate/PowderPeso molecular:194.27Ilginatinib hydrochloride
CAS:<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H21ClFN7Pureza:99.55%Cor e Forma:SolidPeso molecular:425.89Ponatinib Hydrochloride
CAS:<p>Ponatinib Hydrochloride (AP-24534 Hydrochloride) is a hydrochloride of ponatinib.</p>Fórmula:C29H28ClF3N6OPureza:99.88%Cor e Forma:SolidPeso molecular:569.02Pamufetinib
CAS:<p>Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.</p>Fórmula:C27H23FN4O4SPureza:99.39%Cor e Forma:SolidPeso molecular:518.56Petosemtamab
CAS:<p>Petosemtamab (MCLA 158), a dual-action monoclonal antibody targets EGFR & LGR5, used in solid tumor research like HNSCC & CRC.</p>Pureza:> 95% - > 95%Cor e Forma:LiquidPeso molecular:145.97 kDaTriamcinolone acetonide
CAS:<p>Triamcinolone acetonide (Azmacort) is a Corticosteroid.</p>Fórmula:C24H31FO6Pureza:99.61% - 99.91%Cor e Forma:White To Off-White Crystalline PowderPeso molecular:434.50SB220025
CAS:<p>SB220025 is a P38 mitogen-activated protein kinase inhibitor that inhibits p56Lck and PKC, and inhibits angiogenesis.</p>Fórmula:C18H19FN6Pureza:99.44%Cor e Forma:SolidPeso molecular:338.38Losatuxizumab
CAS:<p>Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody with potential anti-tumor activity for the study of advanced malignant solid tumors.</p>Pureza:97.3% (SDS-PAGE); 95.1% (SEC-HPLC) - 97.3% (SDS-PAGE); 95.1% (SEC-HPLC)Cor e Forma:LiquidParsatuzumab
CAS:<p>Parsatuzumab (RG 7414), a monoclonal antibody targeting EGFL7, an immunomodulator.Parsatuzumab inhibits the interaction of EGFL7 with endothelial cells.</p>Pureza:> 95% - > 95%Cor e Forma:LiquidPeso molecular:148.22 kDaAZ7550 hydrochloride
CAS:<p>AZ7550 hydrochloride (AZ7550 hydrochloride ), an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).</p>Fórmula:C27H32ClN7O2Pureza:99.65%Cor e Forma:SolidPeso molecular:522.04Patritumab
CAS:<p>Patritumab (U3-1287), an anti-HER3 antibody, may inhibit tumor growth and cancer cell division in non-small cell lung cancer.</p>Pureza:95.2%Cor e Forma:LiquidPeso molecular:146.97 kDaMargetuximab
CAS:<p>Margetuximab (MGAH-22) is a second generation anti-HER2 monoclonal antibody with anti-tumor activity.</p>Pureza:95.3% (SDS-PAGE); 99.3% (SEC-HPLC) - 95.3% (SDS-PAGE); 99.3% (SEC-HPLC)Cor e Forma:LiquidPanitumumab
CAS:<p>Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).</p>Pureza:95% - 98.1% (SDS-PAGE); 99.4% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:147 kDaCarvedilol phosphate hemihydrate
CAS:<p>Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent.</p>Fórmula:C24H26N2O4·5H2O·H3O4PPureza:99.24% - 99.98%Cor e Forma:SolidPeso molecular:513.49LXH254
CAS:<p>LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.</p>Fórmula:C25H25F3N4O4Pureza:98.3% - 99.92%Cor e Forma:SolidPeso molecular:502.49Tirabrutinib hydrochloride
CAS:<p>Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.</p>Fórmula:C25H23ClN6O3Pureza:99.04% - 99.27%Cor e Forma:SolidPeso molecular:490.94Deferoxamine
CAS:<p>Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine has antioxidant, anti-proliferative and anti-tumor activities. High-Quality, Low-Cost!</p>Fórmula:C25H48N6O8Pureza:99.66% - 99.97%Cor e Forma:SolidPeso molecular:560.68Naphazoline hydrochloride
CAS:<p>Naphazoline hydrochloride (Naphazoline HCl) is an adrenergic vasoconstrictor agent used as a decongestant.</p>Fórmula:C14H15ClN2Pureza:97.93%Cor e Forma:White Crystalline Powder White Crystalline PowderPeso molecular:246.74Naluzotan hydrochloride
CAS:<p>Naluzotan hydrochloride, a hERG K+ blocker (IC50: 3800 nM) and potent 5-HT1A agonist (IC50: ~20 nM, Ki: ~5.1 nM), is used in anxiety and depression studies.</p>Fórmula:C23H39ClN4O3SPureza:99.96%Cor e Forma:SolidPeso molecular:487.1ZX-29
CAS:<p>ZX-29: Strong ALK inhibitor; IC50 - ALK 2.1 nM, L1196M 1.3 nM, G1202R 3.9 nM; triggers autophagy; anti-cancer.</p>Fórmula:C23H28ClN7O3SPureza:98.32%Cor e Forma:SolidPeso molecular:518.03Pemigatinib
CAS:<p>Pemigatinib (INCB054828) is an orally active, selective inhibitor of FGFR(IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively).</p>Fórmula:C24H27F2N5O4Pureza:99.57% - 99.95%Cor e Forma:SolidPeso molecular:487.5Lenvatinib
CAS:<p>Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity.</p>Fórmula:C21H19ClN4O4Pureza:98.46% - 99.69%Cor e Forma:SolidPeso molecular:426.85Formononetin
CAS:<p>Formononetin (Flavosil) is an O-methylated isoflavone and a phytoestrogen from the root of Astragalus membranaceus.</p>Fórmula:C16H12O4Pureza:97.39% - 99.94%Cor e Forma:SolidPeso molecular:268.26Vadadustat
CAS:<p>Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.</p>Fórmula:C14H11ClN2O4Pureza:99.02% - 99.80%Cor e Forma:SolidPeso molecular:306.7Chloramphenicol
CAS:<p>Chloramphenicol (Chloromycetin) is a broad-spectrum antibiotic that inhibits the biosynthesis of bacterial proteins. Cost-effective and quality-assured.</p>Fórmula:C11H12Cl2N2O5Pureza:99.6% - 99.84%Cor e Forma:Needles Or Elongated Plates From Water Or Ethylene Dichloride SolidPeso molecular:323.13Intetumumab
CAS:<p>Intetumumab (CNTO 95) is a fully humanized anti-α(v)-integrin monoclonal antibody that is a radiosensitizer for xenograft tumor-bearing mice.</p>Pureza:97.6% (SDS-PAGE); 97.1% (SEC-HPLC) - 97.6% (SDS-PAGE); 97.1% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:145.6 (kDa)Aprutumab
CAS:<p>Aprutumab, a human FGFR2 monoclonal antibody, targets FGFR2-IIIB/C and is used in antibody-drug conjugates.</p>Pureza:98.69% (SEC-HPLC) - 98.69% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:150 kDaSucralfate
CAS:<p>Sucralfate (Sucrose octasulfate–aluminum complex) is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active</p>Fórmula:C12H54Al16O75S8Pureza:98%Cor e Forma:White Amorphous PowderPeso molecular:2086.75FLT3-IN-20
<p>FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.</p>Fórmula:C28H33N7O2SCor e Forma:SolidPeso molecular:531.67Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Fórmula:C25H27Cl2FN4O4Cor e Forma:SolidPeso molecular:537.41SPP-037
<p>SPP-037 is an orally active selective inhibitor of ST6GAL1, with an IC50 of 3.59 μM. It exhibits anti-migration activity against MDA-MB-231 cells by inhibiting integrin α2,6-sialylation and the integrin-FAK-paxillin pathway. In MDA-MB-231 xenograft mouse models, SPP-037 demonstrates antitumor properties. This compound is applicable in breast cancer research.</p>Fórmula:C36H50ClN3O9SCor e Forma:SolidPeso molecular:735.29563ALK-IN-12
CAS:<p>ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.</p>Fórmula:C24H30ClN6O2PCor e Forma:SolidPeso molecular:500.97MTX-241F
<p>MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.</p>Fórmula:C20H14ClFN6Pureza:98%Cor e Forma:SolidPeso molecular:392.82EGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Fórmula:C17H15N7O5SCor e Forma:SolidPeso molecular:429.41DSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Cor e Forma:Odour SolidMPT0B390
CAS:<p>MPT0B390 is an inhibitor of HDAC and a TIMP3 inducer inhibiting tumor growth, metastasis, and angiogenesis.</p>Fórmula:C17H17N3O5SPureza:99.4%Cor e Forma:SolidPeso molecular:375.4FGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Fórmula:C28H26Cl2N4O3Cor e Forma:SolidPeso molecular:537.44DC-Srci-6649
CAS:<p>DC-Srci-6649 is a potent and selective inhibitor of c-Src kinase, effectively blocking its phosphorylation and stabilizing it in an inactive conformation.</p>Fórmula:C20H22Cl2N2O2SCor e Forma:SolidPeso molecular:425.37AST5902
CAS:<p>AST5902 is the active metabolite of Alflutinib.</p>Fórmula:C27H29F3N8O2Pureza:98%Cor e Forma:SolidPeso molecular:554.57Scr-IN-1
<p>Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.</p>Fórmula:C26H16ClF3N2O3Cor e Forma:SolidPeso molecular:496.87SC209
CAS:<p>SC209, a STRO-002 metabolite from patent WO2021247798, synthesizes anti-EGFR ADCs.</p>Fórmula:C27H44N4O4Cor e Forma:SolidPeso molecular:488.66DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Cor e Forma:LiquidVSLRGDTRG acetate
<p>VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.</p>Cor e Forma:Odour SolidEGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Fórmula:C20H17FN6O2S2Cor e Forma:SolidPeso molecular:456.52Angiogenesis related Compound Library
<p>A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high</p>Cor e Forma:Odour SolidWDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Fórmula:C29H31F3N4O4Cor e Forma:SolidPeso molecular:556.576EGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Fórmula:C24H16N6OS2Pureza:98%Cor e Forma:SolidPeso molecular:468.55Verucopeptin
CAS:<p>Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.</p>Fórmula:C43H73N7O13Cor e Forma:SolidPeso molecular:896.08CNX-500
CAS:<p>CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.</p>Fórmula:C48H68N10O9SPureza:98%Cor e Forma:SolidPeso molecular:961.18SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SCor e Forma:SolidPeso molecular:818.95TL13-12
CAS:<p>TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).</p>Fórmula:C45H53ClN10O10SPureza:98%Cor e Forma:SolidPeso molecular:961.49PROTAC EGFR degrader 7
<p>Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.</p>Fórmula:C46H48N10O6Cor e Forma:SolidPeso molecular:836.94EGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Fórmula:C23H32BrN7O2SPureza:98%Cor e Forma:SolidPeso molecular:550.51EGFR/HER2/DHFR-IN-3
<p>EGFR/HER2/DHFR-IN-3 (compound 4c) serves as an efficacious dual inhibitor specifically targeting EGFR/HER2, exhibiting IC50 values of 0.138 μM for EGFR and 0.</p>Pureza:98%Cor e Forma:Odour SolidJAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SCor e Forma:SolidPeso molecular:548.67GBD-9
CAS:<p>GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).</p>Fórmula:C44H47N9O6Pureza:98%Cor e Forma:SolidPeso molecular:797.9Secretin, canine
CAS:Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.Fórmula:C131H222N44O41Pureza:98%Cor e Forma:SolidPeso molecular:3069.43BCR-ABL-IN-3
CAS:<p>BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.</p>Fórmula:C20H17ClF2N4O3SCor e Forma:SolidPeso molecular:466.89EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Fórmula:C27H37FN8O2Cor e Forma:SolidPeso molecular:524.633FLT3-IN-22
<p>FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.</p>Fórmula:C24H22N6O2Cor e Forma:SolidPeso molecular:426.47MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Fórmula:C50H59ClF4N8O14Cor e Forma:SolidPeso molecular:1107.5Anticancer agent 133
<p>Compound Rh2 (Anticancer agent 133) is a cytotoxic and antimetastatic agent that induces cell cycle arrest, apoptosis, and autophagy.</p>Fórmula:C24H19Cl3N5ORhPureza:98%Cor e Forma:SolidPeso molecular:602.71EGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Fórmula:C22H17F3N4OPureza:98%Cor e Forma:SolidPeso molecular:410.39Multi-kinase-IN-6
<p>Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.</p>Pureza:98%Cor e Forma:Odour SolidEGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Fórmula:C20H17Cl2N3O3Cor e Forma:SolidPeso molecular:418.273PROTAC FAK degrader 1
CAS:<p>PROTAC FAK degrader 1 is a selective and potent degrader of focal adhesion kinase (Fak) (IC50 of 6.5 nM).</p>Fórmula:C47H56F3N9O8S2Pureza:98%Cor e Forma:SolidPeso molecular:996.13Os30
<p>Os30 is a potent fourth-generation EGFR inhibitor, specifically targeting the EGFRC797S-TK mutation with IC50 values of 18 nM for EGFRDel19/T790M/C797S TK and</p>Pureza:98%Cor e Forma:Odour SolidAmuvatinib hydrochloride
CAS:Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Fórmula:C23H22ClN5O3SPureza:98%Cor e Forma:SolidPeso molecular:483.97PROTAC BTK Degrader-6
CAS:<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Fórmula:C45H47N11O6Pureza:98%Cor e Forma:SolidPeso molecular:837.92PROTAC EGFR degrader 6
CAS:<p>PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.</p>Fórmula:C49H57FN12O5Cor e Forma:SolidPeso molecular:913.05Pomalidomide-C5-Dovitinib
CAS:<p>Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC that links Pomalidomide and Dovitinib via a CRBN connector, exhibiting potent antiproliferative activity in</p>Fórmula:C39H38FN9O6Pureza:98%Cor e Forma:SolidPeso molecular:747.77VnP-16
<p>VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activates</p>Fórmula:C82H112N20O17Pureza:98%Cor e Forma:SolidPeso molecular:1649.89Syk Inhibitor II hydrochloride
CAS:<p>Syk signaling is key in lupus. Syk inhibitors reduce inflammation and sepsis severity in FcgRIIb-/- mice, lowering cytokines and organ damage.</p>Fórmula:C14H16ClF3N6OPureza:99.05%Cor e Forma:SolidPeso molecular:376.77BTK-IN-5
CAS:<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Fórmula:C23H32N4O5Cor e Forma:SolidPeso molecular:444.532VSLRGDTRG
CAS:<p>VSLRGDTRG is a synthetic peptide derived from the RGD motif in cadherin17 (CDH17) that binds to the α2β1 integrin, activating its signaling pathways. By promoting high-affinity conformational changes in β1 integrins through the RGD motif, VSLRGDTRG enhances cell adhesion and the phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. This peptide is useful for research on cancers expressing CDH17, such as colorectal and pancreatic cancer.</p>Fórmula:C38H69N15O14Cor e Forma:SolidPeso molecular:960.047Antifibrotic agent 1
<p>Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.</p>Fórmula:C27H23ClN6O2Cor e Forma:SolidPeso molecular:498.1571PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SCor e Forma:SolidPeso molecular:1151.78TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Cor e Forma:Odour SolidMLK3-IN-1
<p>MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.</p>Fórmula:C20H16F6N4O2SCor e Forma:SolidPeso molecular:490.422Apoptosis inducer 35
<p>Apoptosisinducer 35 (Compound 6) is a multi-target inhibitor that reduces the expression of EGFR, AKT, ERK, and P38-MAPKα. It suppresses the proliferation of cancer cells A549 and Jurkat, induces cell cycle arrest at the S phase, and triggers apoptosis (cell death).</p>Fórmula:C23H21ClN8O2S2Cor e Forma:SolidPeso molecular:541.048Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Fórmula:C28H29FN6O2SCor e Forma:SolidPeso molecular:532.63JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OCor e Forma:SolidPeso molecular:407.401DD0-2363
<p>DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.</p>Fórmula:C36H36ClFN6O4Cor e Forma:SolidPeso molecular:671.16PTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Fórmula:C49H51N11O8Pureza:98%Cor e Forma:SolidPeso molecular:922EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PCor e Forma:SolidPeso molecular:805.72SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Fórmula:C68H84N12O9Pureza:98%Cor e Forma:SolidPeso molecular:1213.47Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Fórmula:C33H34N4O3Cor e Forma:SolidPeso molecular:534.648KIT/PDGFRA-IN-1
<p>KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.</p>Fórmula:C26H18F3N5O2Cor e Forma:SolidPeso molecular:489.449HIF-1 inhibitor-4
CAS:<p>HIF-1 inhibitor-4 (HIF-1 inhibitor-4) is a HIF-1 inhibitor with IC50 of 560 nM.</p>Fórmula:C18H19IN2O2Pureza:99.26%Cor e Forma:SolidPeso molecular:422.26INCB-000928
CAS:<p>Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.</p>Fórmula:C30H38N4O3Pureza:98.93%Cor e Forma:SolidPeso molecular:502.65HIF-1 Signaling Pathway Compound Library
<p>A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；</p>Cor e Forma:Odour SolidMY-1576
<p>MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.</p>Fórmula:C25H29ClN8O2Cor e Forma:SolidPeso molecular:509VEGFR-2-IN-36
<p>VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstrated</p>Fórmula:C24H23N7O5Pureza:98%Cor e Forma:SolidPeso molecular:489.48cep-5214
CAS:<p>CEP-5214: Powerful pan VEGF-R tyrosine kinase inhibitor; IC50: 16nM (R1), 8nM (R2), 4nM (R3); effective in cells.</p>Fórmula:C28H28N2O3Cor e Forma:SolidPeso molecular:440.53EGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Fórmula:C27H31N3O2Cor e Forma:SolidPeso molecular:429.24163PROTAC EGFR degrader 4
CAS:<p>PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).</p>Fórmula:C55H70N12O4SCor e Forma:SolidPeso molecular:995.29Anticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Cor e Forma:Odour SolidLyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Cor e Forma:SolidPeso molecular:915.028Sorafenib-d4
CAS:<p>Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.</p>Fórmula:C21H16ClF3N4O3Pureza:98%Cor e Forma:SolidPeso molecular:468.85AG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Cor e Forma:SolidPeso molecular:352.21SNIPER(ABL)-015
<p>SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5</p>Fórmula:C58H70F3N9O9Pureza:98%Cor e Forma:SolidPeso molecular:1094.23PF15 TFA
<p>PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.</p>Fórmula:C46H50F3N13O8Pureza:98%Cor e Forma:SolidPeso molecular:969.97VEGFR-2-IN-64
<p>VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.</p>Fórmula:C72H123N9O6Cor e Forma:SolidPeso molecular:1210.8PROTAC BCR-ABL1 ligand 1
CAS:<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Fórmula:C17H12F3N3O2Cor e Forma:SoildPeso molecular:347.29PROTAC FLT-3 degrader 1
CAS:<p>PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.</p>Fórmula:C52H61N9O9S2Pureza:98%Cor e Forma:SolidPeso molecular:1020.23VEGFR/PARP-IN-1
<p>VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.</p>Fórmula:C29H27N9OPureza:98%Cor e Forma:SolidPeso molecular:517.58Si5-N14
CAS:<p>Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.</p>Fórmula:C78H160N6O5Si2Cor e Forma:SolidPeso molecular:1318.31AKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Fórmula:C17H14N6Pureza:99.88%Cor e Forma:SolidPeso molecular:302.33DSPE-PEG2000-A7R
<p>DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.</p>Cor e Forma:Odour SolidMersalyl
CAS:<p>Mersalyl is an organic mercurial diuretic.</p>Fórmula:C13H16HgNNaO6Cor e Forma:SolidPeso molecular:505.854DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidAXL/Angiokinase-IN-1
<p>AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.</p>Fórmula:C31H34ClN5O2Cor e Forma:SolidPeso molecular:544.09AMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Cor e Forma:Odour LiquidALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Fórmula:C29H39ClN7O2PCor e Forma:SolidPeso molecular:584.1PLM-101
<p>PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.</p>Fórmula:C22H22FN5O2Cor e Forma:SolidPeso molecular:407.44RR-src
CAS:<p>Tyrosine kinase substrate peptide</p>Fórmula:C64H106N22O21Pureza:98%Cor e Forma:Lyophilized PowderPeso molecular:1519.66Multi-kinase-IN-4
<p>Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.</p>Fórmula:C21H20ClFN2OSPureza:98%Cor e Forma:SolidPeso molecular:402.91SNIPER(ABL)-047
<p>SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,</p>Fórmula:C67H82F3N11O9SPureza:98%Cor e Forma:SolidPeso molecular:1274.5SI-2
CAS:<p>SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.</p>Fórmula:C15H15N5Pureza:98.4%Cor e Forma:SolidPeso molecular:265.31DB1113
CAS:<p>DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.</p>Fórmula:C59H68F3N13O6SCor e Forma:SolidPeso molecular:1144.31Wu-5
CAS:<p>Wu-5 is a potent USP10 inhibitor that inhibits FLT3 and AMPK pathways, promoting the breakdown of FLT3-ITD and inducing apoptosis.</p>Fórmula:C15H13NO7SPureza:99.29%Cor e Forma:SoildPeso molecular:351.33PROTAC BCR-ABL Degrader-1
<p>PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and</p>Fórmula:C43H40N10O6Pureza:98%Cor e Forma:SolidPeso molecular:792.84FLT3/VEGFR2-IN-1
<p>FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.</p>Fórmula:C29H35N7O5Cor e Forma:SolidPeso molecular:561.63(R)-3-Hydroxy Midostaurin
CAS:<p>(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.</p>Fórmula:C35H30N4O5Pureza:98%Cor e Forma:SolidPeso molecular:586.648Lyn peptide inhibitor
CAS:<p>Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.</p>Fórmula:C115H184N30O24Pureza:98%Cor e Forma:SolidPeso molecular:2370.91MHES0488A
<p>MHES0488A is a selective humanized antibody targeting HER2, with a KD value of 0.8 nM. It constitutes the antibody portion of DHES0815A. Upon cellular internalization, MHES0488A is transported to lysosomes, releasing PBD-monoamide into the nucleus, where it alkylates DNA, inducing DNA damage and apoptosis. It shows potential for research in cancers such as HER2-positive breast cancer and gastric cancer.</p>Cor e Forma:Odour LiquidTrastuzumab emtansine
CAS:<p>Trastuzumab emtansine is a HER2-targeted ADC for advanced breast cancer, combining trastuzumab with DM1 cytotoxicity.</p>Pureza:98%Cor e Forma:LiquidSNIPER(ABL)-058
CAS:<p>SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL protein</p>Fórmula:C62H75N11O9SPureza:98%Cor e Forma:SolidPeso molecular:1150.39BMS-599626 2HCL(714971-09-2 Free base)
CAS:<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Fórmula:C27H29Cl2FN8O3Pureza:99.11%Cor e Forma:Odour SolidPeso molecular:603.47FAK-IN-24
CAS:<p>FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.</p>Fórmula:C39H45Cl2F3N8O3Cor e Forma:SolidPeso molecular:801.728SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74Multi-kinase-IN-5
<p>Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,</p>Fórmula:C19H15N5O2SCor e Forma:SolidPeso molecular:377.42DSPE-PEG5000-A7R
<p>DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Cor e Forma:Odour SolidIbrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Fórmula:C56H80N12O9SPureza:98%Cor e Forma:SolidPeso molecular:1097.39TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Cor e Forma:Odour SolidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Fórmula:C26H20ClFN4OSCor e Forma:SolidPeso molecular:490.98MP-RM-1
<p>MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.</p>Cor e Forma:Odour LiquidHER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Fórmula:C42H77N9O11Pureza:98%Cor e Forma:SolidPeso molecular:884.11ALK-IN-9
CAS:<p>ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.</p>Fórmula:C20H21FN6O3Cor e Forma:SolidPeso molecular:412.425FGFR-IN-19
<p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>Fórmula:C36H42N12O6Cor e Forma:SolidPeso molecular:738.33503DSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidDuligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Cor e Forma:LiquidBV02
CAS:<p>BV02 blocks 14-3-3 interactions, useful in chronic myeloid leukemia research, targets T315I mutant and wild-type Bcr-Abl cells.</p>Fórmula:C20H15N3O5Pureza:99.82%Cor e Forma:SolidPeso molecular:377.35ML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Fórmula:C47H53BrCl2N10O7SPureza:98%Cor e Forma:SolidPeso molecular:1052.86Coumermycin A1
CAS:<p>Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.</p>Fórmula:C55H59N5O20Cor e Forma:SolidPeso molecular:1110.092DD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Fórmula:C55H62N10O8Cor e Forma:SolidPeso molecular:991.163LC-SF-14
<p>LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.</p>Fórmula:C44H50Cl3N13O5SCor e Forma:SolidPeso molecular:977.28442IOX2-NH2-Methyl
<p>IOX2-NH2-Methyl is a modified form of IOX2. IOX2 is a specific inhibitor of PHD2 (prolyl-hydroxylase-2), capable of upregulating HIF-1α expression and suppressing ROS production. IOX2-NH2-Methyl is employed in investigations of platelet and thrombus formation.</p>Fórmula:C20H19N3O5Pureza:97.64% - 99.31%Cor e Forma:SolidPeso molecular:381.39EGFR-IN-151
<p>EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.</p>Cor e Forma:Odour SolidCetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Cor e Forma:Odour LiquidOK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Fórmula:C42H62N14O9Pureza:98%Cor e Forma:SolidPeso molecular:907.03MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Cor e Forma:SolidPeso molecular:993.47SIAIS178
CAS:<p>SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).</p>Fórmula:C50H62ClN11O6S2Pureza:98.07%Cor e Forma:SolidPeso molecular:1012.68EGFR/BRAFV600E-IN-4
<p>EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.</p>Fórmula:C22H16N4OSCor e Forma:SolidPeso molecular:384.45SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Fórmula:C25H29F3N4O3Cor e Forma:SolidPeso molecular:490.52SNIPER(ABL)-033
CAS:<p>SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein</p>Fórmula:C61H73F3N10O9S2Pureza:98%Cor e Forma:SolidPeso molecular:1211.42Trastuzumab envedotin
<p>Trastuzumab envedotin (DP303c) is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It consists of the anti-HER2 antibody DP001 linked to the microtubule polymerization inhibitor MonomethylauristatinE (MMAE) through a cleavable linker. This compound is utilized in research involving HER2-positive solid tumors such as breast cancer, colorectal cancer, and gastric cancer.</p>Cor e Forma:Odour LiquidAnti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Cor e Forma:Odour LiquidYH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Cor e Forma:Odour LiquidMulti-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Pureza:98%Cor e Forma:Odour SolidDSPE-PEG1000-A7R
<p>DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Cor e Forma:Odour SolidAD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Fórmula:C22H20F3N7OPureza:99.05%Cor e Forma:SoildPeso molecular:455.44BTK inhibitor 19
CAS:<p>BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).</p>Fórmula:C25H24F3N7O3Cor e Forma:SolidPeso molecular:527.508PST3.1a
CAS:<p>PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).</p>Fórmula:C32H33O6PCor e Forma:SolidPeso molecular:544.57EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Fórmula:C49H32N12O2S2Pureza:98%Cor e Forma:SolidPeso molecular:884.99BTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Cor e Forma:Odour SolidALK protein ligand-1
CAS:<p>ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.</p>Fórmula:C24H29ClN6O3SCor e Forma:SolidPeso molecular:517.043PROTAC FGFR1 degrader-1
<p>PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.</p>Fórmula:C46H54N8O8Cor e Forma:SolidPeso molecular:846.97Hck-IN-2
<p>Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.</p>Fórmula:C36H35FN6O10Cor e Forma:SolidPeso molecular:730.696COVA208
<p>COVA208 is a bispecific FynomAb targeting HER2, consisting of a fusion protein of an antibody and a FynSH3-derived binding protein. It induces the degradation of HER2, reducing the levels of HER2, HER3, and EGFR, effectively blocking downstream signaling pathways such as HER3-PI3K-AKT and MAPK, and inducing apoptosis in tumor cells. COVA208 shows promise for research in cancers like HER2-positive breast, gastric, and colorectal cancers.</p>Cor e Forma:Odour LiquidPACAP-38 (31-38), human, mouse, rat TFA
<p>PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.</p>Fórmula:C49H84F3N17O13Pureza:98%Cor e Forma:SolidPeso molecular:1176.29EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Fórmula:C30H20N6OSPureza:98%Cor e Forma:SolidPeso molecular:512.58HG-7-85-01
CAS:<p>HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.</p>Fórmula:C31H31F3N6O2SPureza:98.08%Cor e Forma:SolidPeso molecular:608.68IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Cor e Forma:Odour LiquidIMC-D11
<p>IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.</p>Cor e Forma:Odour LiquidE7090
CAS:<p>E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.</p>Fórmula:C32H37N5O6Cor e Forma:SolidPeso molecular:587.67ABP-102
<p>ABP-102 (CT P72) is a bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for targeting HER2 overexpressing tumors.</p>Cor e Forma:Odour LiquidK882
<p>K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.</p>Fórmula:C18H16N2O2Cor e Forma:SolidPeso molecular:292.33
